VDPP v. Medtronic: 3D Spectacles Patents Dismissed With Prejudice in 49 Days
VDPP, LLC filed a patent infringement action against Medtronic, Inc. in the Southern District of Florida asserting two patents covering continuous adjustable 3D filter spectacles technology. The case closed just 49 days after filing when VDPP voluntarily dismissed with prejudice — ending all claims permanently and with each party bearing its own costs.
Rapid voluntary exit: VDPP drops 3D spectacles claims against Medtronic
On January 14, 2025, VDPP, LLC filed suit against Medtronic, Inc. in the U.S. District Court for the Southern District of Florida (Case No. 1:25-cv-20206), asserting infringement of US9699444B2 and US9716874B2. Both patents relate to continuous adjustable 3Deeps filter spectacles for stereoscopic 3D viewing, including control methods and multi-layered variable tint materials enabling faster state transitions. The case was assigned to Judge Rodney Smith in Fort Lauderdale.
The case concluded on March 5, 2025 — just 49 days after filing — when the court entered an order granting VDPP’s Notice of Voluntary Dismissal With Prejudice. Dismissal with prejudice is a full and permanent termination: VDPP cannot refile the same claims against Medtronic on these patents. Each party was ordered to bear its own attorney’s fees and costs, except as otherwise agreed between the parties privately.
A dismissal this swift — before Medtronic even appeared on record with counsel — is consistent with pre-suit settlement or licensing resolution, though the public record is silent on any financial terms. The with-prejudice designation is notable: it suggests VDPP obtained something of value in exchange for relinquishing its right to refile, rather than simply abandoning a weak case. What drove the resolution, and whether a license was granted, remains undisclosed.
Filing to Voluntary dismissal in 49 days
49 days — well below the median district court patent case duration of 2+ years
Dismissed with prejudice: what the voluntary exit means for both parties
Voluntary dismissal with prejudice permanently bars re-litigation
Under Federal Rule of Civil Procedure 41(a), a plaintiff may voluntarily dismiss an action. When the dismissal is ‘with prejudice,’ it operates as a final adjudication on the merits. VDPP cannot assert US9699444B2 or US9716874B2 against Medtronic in any future action. This is a stronger procedural commitment than a without-prejudice dismissal, which would permit refiling.
Rule 41 — permanent barVDPP surrenders its right to refile — typically signals a resolution
Accepting a with-prejudice dismissal is a significant concession by VDPP. Patent holders rarely agree to permanently extinguish claims unless they have achieved an acceptable outcome — such as a licensing agreement, royalty arrangement, or other commercial resolution. The public record does not disclose any such terms, so the specific value exchanged, if any, remains unknown.
Possible undisclosed licenseMedtronic secures a permanent shield on these two patents
Medtronic benefits from a with-prejudice dismissal because it eliminates the risk of VDPP reasserting the same 3D spectacles patents in a future action. Medtronic’s counsel does not appear on the public docket, suggesting resolution was reached very early — possibly before formal litigation posture was established. Each party bearing its own costs is standard in early consensual resolutions.
Permanent claim bar securedPatents survive but enforceability against Medtronic is now extinguished
US9699444B2 and US9716874B2 remain active patents and could still be asserted against other parties in the 3D display or medical visualization space. The dismissal with prejudice affects only Medtronic. Companies operating in stereoscopic display, adjustable optical filtering, or variable tint lens technology should note that VDPP retains enforcement rights against third parties not covered by this dismissal.
Third-party risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | VDPP, LLC | Company | 3D display technology IP holding entity — holder of US9699444B2 and US9716874B2Search in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | Medtronic, Inc. — global medical device and technology corporationSearch in Eureka ↗ |
| Plaintiff counsel | Victoria Elisabeth Brieant | Attorney | Counsel for VDPP, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Law Office of Victoria E. Brieant | Law Firm | Representing VDPP, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Rodney Smith | Judge | Florida Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order adopts the precise language of VDPP’s voluntary dismissal notice, entering dismissal ‘with prejudice’ and specifying that each party bears its own fees and costs. The with-prejudice designation is the operative term: it forecloses any future action by VDPP on these two patents against Medtronic. The cost-bearing provision — each side paying its own fees ‘except as otherwise agreed’ — preserves room for a private settlement arrangement not reflected in the public docket, consistent with a negotiated resolution reached before substantive litigation began.
US9699444B2 & US9716874B2 — Continuous Adjustable 3D Filter Spectacles
US9699444B2 covers continuous adjustable 3Deeps filter spectacles optimized for stereoscopic 3D viewing, including the associated control method and means, and a system for generating and displaying modified video. US9716874B2 addresses faster state transitioning in such spectacles using multi-layered variable tint materials. Both patents originate from application numbers in the US15 series, suggesting a related family filed in close succession, likely targeting overlapping claims in the adaptive optical display space.
The strategic significance of these patents extends beyond consumer 3D entertainment. Variable tint materials and stereoscopic display control methods have potential applications in surgical visualization, augmented reality headsets, and medical imaging displays — sectors where Medtronic operates. Competitors in adaptive optics, heads-up display systems, or medical visualization should conduct a thorough landscape assessment around VDPP’s portfolio, as continuation applications may broaden coverage beyond the two asserted patents.
Should your team run an FTO against US9699444B2 and US9716874B2?
Any company developing or commercializing products involving adjustable stereoscopic display optics, variable tint lens systems, or 3D filter eyewear — including applications in medical visualization, surgical displays, AR/VR headsets, or consumer 3D viewing — should assess freedom to operate against VDPP’s asserted patents. The with-prejudice dismissal against Medtronic does not extend any protection to third parties.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to rapidly map claim scope for US9699444B2 and US9716874B2, identify related family members and continuations that may extend coverage, and surface design-around pathways. With VDPP demonstrating active enforcement behavior, early-stage FTO analysis is materially lower cost than defending a district court action.
Run a freedom-to-operate analysis on US9699444B2 to assess your product’s exposure
Run FTO in Eureka →Similar 3D display and optical technology patent cases in U.S. district courts
Explore related patent infringement actions involving stereoscopic display, adaptive optics, and variable tint lens technology filed in U.S. district courts.
What this case signals for the 3D display and optical technology IP landscape
A 49-day lifecycle with no merits ruling raises important questions for companies operating near VDPP’s patent portfolio.
With-prejudice exits in 49 days strongly suggest pre-litigation settlement activity
When a plaintiff dismisses with prejudice before the defendant even files an appearance, it typically suggests the parties reached an understanding — whether a license, covenant not to sue, or commercial arrangement — outside the formal litigation process. IP teams monitoring VDPP’s enforcement activity should treat this pattern as consistent with an active licensing program.
VDPP’s two asserted patents remain live enforcement tools against other defendants
The dismissal resolves only the claim against Medtronic. US9699444B2 and US9716874B2 covering 3D filter spectacles and variable tint materials retain full enforceability. Any company in the stereoscopic display, medical visualization, or adaptive optics space that has not assessed these patents faces continued exposure.
VDPP v Medtronic — key questions answered
VDPP, LLC filed a patent infringement action against Medtronic, Inc. in the Southern District of Florida on January 14, 2025, asserting US9699444B2 and US9716874B2. The case was voluntarily dismissed with prejudice by VDPP on March 5, 2025 — just 49 days after filing — with each party bearing its own costs.
Dismissal with prejudice permanently bars VDPP from asserting US9699444B2 or US9716874B2 against Medtronic in any future litigation. The patents themselves remain valid and enforceable against other parties. The dismissal resolves only VDPP’s claims against Medtronic specifically.
VDPP asserted two patents: US9699444B2, covering continuous adjustable 3Deeps filter spectacles for stereoscopic viewing with associated control methods, and US9716874B2, covering faster state transitioning in 3D filter spectacles using multi-layered variable tint materials. Both relate to adaptive optical display technology.
The public record does not disclose any settlement or licensing terms. However, a with-prejudice voluntary dismissal filed before the defendant entered an appearance — and with a cost-bearing provision preserving private agreements — is consistent with a negotiated resolution such as a license or covenant not to sue. This cannot be confirmed from available court documents.
Yes. The dismissal with prejudice affects only Medtronic. Both patents remain active and enforceable against any other party operating in the stereoscopic display, 3D filter optics, or variable tint lens space. Companies in adjacent sectors — including medical visualization and AR/VR — should assess their exposure to these patents independently.
PatSnap Eureka searches patents and litigation data to answer instantly.